Here are relevant reports on : animal-disease-diagnostics-market
-
Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics)-Forecast to 2030
The predictive clinical biomarkers market, valued at US$7.84 billion in 2024, stood at US$8.49 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$14.69 billion by the end of the period. he market for predictive clinical biomarkers is growing rapidly as the healthcare industry shifts toward personalized and predictive medicine.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Middle East & Africa In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Infectious Disease) - Forecast to 2031
The Middle East & Africa in vitro diagnostics (IVD) market, valued at USD 3.33 billion in 2025, stood at USD 3.49 billion in 2026 and is projected to advance at a resilient CAGR of 4.8% from 2026 to 2031, culminating in a forecasted valuation of USD 4.42 billion by the end of the period.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Latin America In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Disease) - Forecast to 2031
The Latin America in vitro diagnostics (IVD) market, valued at USD 5.48 billion in 2025, stood at USD 5.87 billion in 2026 and is projected to advance at a resilient CAGR of 6.7% from 2026 to 2031, culminating in a forecasted valuation of USD 8.13 billion by the end of the period. The increasing demand for diagnostic services, along with the growing need for routine and specialized testing, is driving the market. Investments in lab infrastructure, combined with the adoption of automated and standardized diagnostic procedures, contribute to increasing test volumes in both the public and private healthcare sectors.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Sexually Transmitted Diseases Diagnostics Market by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC) and Geography - Global Forecast to 2027
The STDs diagnostics market size is projected to reach $99,431.6 million by 2027 from $91,441.5 million in 2022, at a CAGR of 5.6% during the forecast period. Sexually transmitted diseases diagnostics market is driven by factors such as global prevalence of HIV, CT/NG, and other STDs and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Molecular Quality Controls Market Product (Independent Control, Instrument Specific Control (PCR, DNA Sequencing), Application (Infectious Disease Diagnostics), Analyte type, End User (Hospitals, Diagnostic Lab), Region- Global Forecast to 2028
The global molecular quality controls market, valued at US$0.2 billion in 2022, stood at US$0.2 billion in 2023 and is projected to advance at a resilient CAGR of 6.6% from 2023 to 2028, culminating in a forecasted valuation of US$0.3 billion by the end of the period. The growth of this market is primarily driven by the increasing number of accredited clinical laboratories, growing adoption of third-party quality controls, and increasing government funding for genomic projects.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030
Global ASEAN point of care diagnostics market valued at $1.05B in 2024, reached $1.08B in 2025, and is projected to grow at a robust 4.7% CAGR, hitting $1.36B by 2030. The increasing incidence of chronic conditions, especially diabetes, generates the demand for regular monitoring and early detection, boosting the need for rapid & accurate POC testing solutions
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
C – Reactive Protein Testing Market by Assay Type (ELISA, Turbidimetric, Immunoturbidimetric), Application (Cardiovascular, Inflammatory Disease, Rheumatoid Arthritis, Cancer), End User (Hospitals, Clinics, Diagnostics Labs) - Global Forecast to 2023
The Global C-Reactive Protein Testing market is expected to reach USD 1.75 billion by 2023 from USD 1.62 billion in 2018, growing at a CAGR of 1.5 % from 2018 to 2023. Growing occurrences of Non Communicable Diseases (NCDs) such as Cardiovascular Diseases, Diabetes and other inflammatory diseases are the major drivers for this market. Point of Care technology for CRP testing is also being used for diagnostic purposes.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029
The global DNA diagnostics market, valued at US$12.3 billion in 2023, stood at US$13.3 billion in 2024 and is projected to advance at a resilient CAGR of 9.7% from 2024 to 2029, culminating in a forecasted valuation of US$21.2 billion by the end of the period. Growth in the market is primarily driven by the technological improvements in the DNA diagnostics industry and the growing need for personalized treatment and early disease diagnosis in developing nations. Also, the increased investments by healthcare-based companies are majorly contributing to growth of the market.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024
The Lymphedema Diagnostics Market is expected to grow from USD 24 million in 2019 to USD 35 million by 2024, at a CAGR of 7.4% during the forecast period. The major players operating in the lymphedema diagnostics market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030
Global respiratory diagnostics market valued at $5.84B in 2024, reached $6.17B in 2025, and is projected to grow at a robust 6.5% CAGR, hitting $9.02B by 2030. The major factors driving the growth of this market include the rising incidence of respiratory disorders, the expanding geriatric population and the rise in sedentary lifestyles, growing awareness about respiratory health, and advancements in diagnostic technologies.
- Published: February 2025
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
